Who
Nikhil Lalwani
President & CEO
Company insider
Files Form 4 as: President & CEO, ANI Pharmaceuticals.
In numbers
- Trades disclosed
- 58
- Buys
- 1
- Sells
- 11
- Bought
- $200K
- Sold
- $25.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Sep 2020
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $388K5,400 at $71.89 | filing |
| 15 Sep 2026filed 16 Sep 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $383K5,400 at $71.00 | filing |
| 15 Sep 2026filed 16 Sep 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $383K5,400 at $71.00 | filing |
| 25 Aug 2026filed 26 Aug 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $401K5,400 at $74.30 | filing |
| 25 Aug 2026filed 26 Aug 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $401K5,400 at $74.30 | filing |
| 11 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4.3M55,000 at $77.57 | filing |
| 11 May 2026filed 13 May 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4.3M55,000 at $77.57 | filing |
| 7 Mar 2026filed 10 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.3M17,060 at $74.04 | filing |
| 7 Mar 2026filed 10 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1.3M17,060 at $74.04 | filing |
| 28 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $903K12,217 at $73.90 | filing |
| 28 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $903K12,217 at $73.90 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | $5.8M75,592 at $77.15 | filing |
| 26 Feb 2026filed 2 Mar 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | $5.8M75,592 at $77.15 | filing |
| 14 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $797K10,298 at $77.36 | filing |
| 14 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $797K10,298 at $77.36 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $896K11,688 at $76.70 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $896K11,688 at $76.70 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $2.3M30,659 at $76.25 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $2.3M30,659 at $76.25 | filing |
| 12 Aug 2025filed 14 Aug 2025 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4.9M56,960 at $85.93 | filing |
News
ANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 5,400 Sharesthemarketsdaily.com · 17 Sep 2026ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETANIP · manilatimes.net · 23 Oct 2026ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease StudyANIP · rttnews.com · 12 Oct 2026
1 headline in the last 90 days name Nikhil Lalwani; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.